ingredientsour brandssustainabilitywhy Givaudan?expert insightsContact Us

The science behind Ellirose™

back to
Ellirose™

A hibiscus ingredient for urinary tract health supported by patents

According to the NIH, issues associated with urinary health can disrupt day-to-day life. When people have urinary health issues, they may limit social interactions and have a harder time getting tasks done at home or at work. Treatment for urinary health issues may include behavioral and lifestyle changes, exercises and others.² Dietary supplementation may help support urinary comfort. In a category dominated by cranberry products, Ellirose™ offers a unique mechanism to support urinary tract health. Cranberry has an anti-adhesion action, minimizing the binding of_ E. coli_ to the bladder wall and therefore inhibiting its ability to infect the mucosal cells of the urinary tract.³ Conversely, the hibiscus extract used in Ellirose™ demonstrates inhibitory activity on _E. coli_ ¹ ⁴, which is complementary to the anti-adhesion activity of cranberry ingredients.

56%
reduction in urinary symptoms after 3 months⁴
89%
reduction in urinary symptoms after 6 months⁴

Strong and rapid inhibitory activity

In vitro studies have shown that dried Hibiscus sabdariffa calyx – the leafy casing that protects the flower bud – demonstrates strong and rapid inhibitory activity in vitro against E.coli. In just 24 hours, the E.coli content of the growth medium was reduced by 5 log.⁴ It’s also been found to work as an inhibitory agent against Candida albicans, which is a common cause of urinary discomfort.⁵

Reduction in frequency of urinary discomfort

A randomised, double-blind, placebo-controlled study was conducted in forty women ages 26-48 with a history of recurrent urinary discomfort.⁴ Women who consumed 200 mg of Ellirose™ daily showed a significant decrease of 56% in urinary symptoms compared to the three months before the study started (p<0.01). Over a period of six months, the efficacy of Ellirose™ was further enhanced, as signified by a decrease in the incidence of symptoms of 89% (p<0.01).

Learn More

Learn More

References
Disclaimer
This web page is intended to provide business-to-business education and information. Its purpose is not intended to communicate to end consumers. Ingredient information is for educational purposes only; specific ingredients are not intended to prevent, treat, mitigate or cure any disease states. This information is not intended to be used in final consumer products and any use or reference of the intellectual property of Givaudan in the final product may only be made with Givaudan’s prior written permission. The information provided may or may not be applicable to, or satisfy, all regulatory requirements for all global regions. Specific regulatory requirements must be evaluated to ensure compliance within the individual countries and regions.
contactsprivacy policyterms and conditions
*